Dr Jane Wolstenholme
Jane Wolstenholme
BA(Hons), MSc, PhD
Associate Professor of Health Economics
I have over 25 years of experience in conducting economic evaluations for health policy makers and exploring methodological issues relating to the design and analysis of economic evaluations. I have been a health economist at HERC since 1998, prior to that a research associate at the University of Nottingham.
My research programme has focused on the health economics of cancer, with current research on trial-based evaluations and methodology related to prostate, breast and head and neck cancer. Previous published research relates to the economic evaluation of interventions for prostate, breast, cervical and lung cancer.
My main research interests include designing and conducting economic evaluations alongside trials and cost-effectiveness models. I am principal investigator and co-applicant on a wide variety of funded research projects, across a number of disease areas and health-care technologies, including cancer, chronic kidney disease, obesity, mental health, point of care and in-vitro diagnostics.
I am a health economics adviser for the NIHR RDS South Central and the lead health economist for the NIHR Community Healthcare Medtech and In Vitro Diagnostics Co-operative, Oxford University.
I supervise MSc and DPhil students. Examples of current doctoral research:
- Exploring the cost-effectiveness of chronic disease prevention strategies using local area chronic disease scenario modelling.
- Developing a modelling framework for providing individualised estimates of comparative outcomes and cost-effectiveness for competing radiotherapy technologies in cancer patients.
I have published widely and I’m co-author of a major OUP text book ‘Applied Methods of Cost-effectiveness Analysis in Health Care’.
Recent publications
-
The early use of Antibiotics for At-risk children with InfluEnza in Primary Care (the ARCHIE programme)
Wang K. et al, (2023), Programme Grants for Applied Research, 1 - 57
-
Protocol for the TRANSLATE prospective, multi-centre, randomised clinical trial.
Bryant RJ. et al, (2023), BJU Int
-
Individualised Estimation of Quality-adjusted Survival Benefit and Cost-effectiveness of Proton Beam Therapy in Intermediate-stage Hodgkin Lymphoma.
Jones DA. et al, (2023), Clin Oncol (R Coll Radiol)
-
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.
Thomson DJ. et al, (2023), Clin Transl Radiat Oncol, 38, 147 - 154
-
Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial.
Hill NR. et al, (2022), Trials, 23